#ASH20: David Altshuler and the Vertex/CRISPR team hit a historic milestone in the hunt for a curative gene editing approach to sickle cell disease, beta thalassemia
Back in the mid-80s, David Altshuler worked in Richard Mulligan’s famous Harvard lab, focused on hemoglobinopathies and the glimmering promise of a gene therapy for sickle cell disease.
Today, 35 years later, the Broad co-founder and chief scientist at Vertex and his partners at CRISPR Therapeutics have reached a sign post on the world’s most advanced gene editing program that points to a potential cure for both sickle cell disease and beta thalassemia. And Altshuler can see the finish line ahead.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.